A Parallel, Three Arm, Open-label, Multi-dose Pharmacokinetic Study of Dalfampridine-ER 7.5 mg Twice Daily in Both Healthy Volunteers and Those With Mild and Moderate Renal Impairment.
Phase of Trial: Phase I
Latest Information Update: 30 Sep 2013
At a glance
- Drugs Fampridine (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- 06 Nov 2012 Primary endpoint amended as reported by ClinicalTrials.gov.
- 02 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Sep 2011 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.